Lung Cancer Trial, Recruiting NCT07613424 Sponsor: AstraZeneca Condition: Lung Cancer
Back to Lung Cancer

Lung Cancer Trial, Recruiting

NCT07613424
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must be 18 years old or older at the time you sign the consent form.
  • You have been diagnosed with a type of lung cancer called non-small cell lung cancer (NSCLC) that either cannot be removed by surgery (Stage IIIB or IIIC), has spread to other parts of the body, or has come back (Stage IV), confirmed by a tissue or cell test.
  • You are willing to provide a tissue sample: either a biopsy taken after your current diagnosis and before starting any cancer treatment (requiring at least 16 prepared tissue slides), or a surgical tissue sample if your cancer has come back and you either had no additional treatment after surgery, or only had chemotherapy after surgery and your cancer returned more than 6 months after finishing that chemotherapy (requiring at least 13 prepared tissue slides, taken within the last 2 years).
  • You are able to understand and sign a consent form agreeing to follow the study's requirements.

Who may not be able to join:

  • You currently have another type of cancer, or have had another invasive (spreading) cancer in the past 5 years — though some exceptions may apply, such as certain early-stage cancers fully treated at least 3 years ago, non-invasive cancers, a specific type of thyroid cancer, or certain skin cancers (confirm with trial site).
  • You have already received radiation therapy or systemic (whole-body) treatment specifically for your current stage of NSCLC, unless you only just started a first-line treatment within the past month before signing the consent form.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 1-877-240-9479

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
2 June 2026
Est. completion
31 March 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

OPA/PPA/NPA

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov